Table 1.
Characteristics and serum levels of sCD163 in patients with cutaneous melanoma.
| Age (y) | Sex | Location | Body weight (kg) | Prior systemic therapy | Efficacy at 3 months | Increase of sCD163 | Change ratio of sCD163 (%) | |
|---|---|---|---|---|---|---|---|---|
| No. 1 | 61–70 | M | Extremities | 63.2 | DAV+IFN-β | PR | 11.556 | 149 |
| No. 2 | 61–70 | M | Extremities | 48 | – | PR | 50.8525 | 227.8 |
| No. 3 | 81–90 | F | Extremities | 48.7 | DPCP | PR | 12.676 | 152.7 |
| No. 4 | 61–70 | M | Extremities | 70.4 | DAV+IFN-β | PR | 13.27122 | 146.2 |
| No. 5 | 61–70 | M | Extremities | 58.5 | DAV+IFN-β | PR | 7.17709 | 127 |
| No. 6 | 61–70 | M | Lip | 69.8 | DAV+IFN-β | PR | 5.834 | 123.1 |
| No. 7 | 71–80 | M | Trunk | 59.4 | – | PR | 21.49956 | 133.4 |
| No. 8 | 71–80 | F | Extremities | 68 | – | PR | −12.9704 | 81.6 |
| No. 9 | 31–40 | F | Extremities | 55.4 | DTIC+IFN-β | PR | 24.5042321 | 189.5 |
| No. 10 | 71–80 | M | Extremities | 61.2 | – | PR | 3.36944 | 109.5 |
| No. 11 | 51–60 | F | Extremities | 41.7 | – | CR | 2.109187 | 170.7 |
| No. 12 | 81–90 | M | Unknown | 68.3 | – | PR | 3.07118 | 111.3 |
| No. 13 | 71–80 | F | Extremities | 50.1 | IFN-α | PR | 35.7011169 | 158.5 |
| No. 1 | 51–60 | M | Trunk | 68.7 | – | SD | 1.5625 | 107.5 |
| No. 2 | 31–40 | F | Extremities | 60.8 | CBDCA+PTX | PD | −9.6755 | 82.4 |
| No. 3 | 61–70 | M | Trunk | 62 | DTIC+IFN-β | PD | 2.884 | 109.6 |
| No. 4 | 81–90 | F | Extremities | 44.9 | IFN-α | PD | −0.333 | 98.7 |
| No. 5 | 71–80 | M | Head and neck | 59.2 | IFN-β | SD | 0.998 | 103.6 |
| No. 6 | 81–90 | F | Trunk | 41.9 | IFN-β | PD | 6.76453 | 116.9 |
| No. 7 | 91–100 | M | Extremities | 55 | IFN-β | PD | 4.02405 | 113 |
| No. 8 | 71–80 | M | Extremities | 85.9 | IFN-β | SD | −5.10307 | 89.9 |
| No. 9 | 31–40 | M | Extremities | 73 | TMZ | PD | −16.806 | 67.8 |
| No. 10 | 61–70 | M | Extremities | 55 | anti-CCR4 Abs | PD | 2.706 | 115.4 |
| No. 11 | 61–70 | F | Extremities | 66.3 | DAV+IFNβ | PD | 0.653 | 103.4 |
| No. 12 | 61–70 | M | Head and neck | 55 | DTIC | PD | −0.094 | 99.6 |
| No. 13 | 61–70 | M | Extremities | 115.4 | DAV+IFN-β | SD | 0.177 | 100.5 |
| No. 14 | 61–70 | M | Extremities | 77.6 | IFN-β | PD | −61.59461 | 35.5 |
| No. 15 | 81–90 | F | Unknown | 47.8 | – | SD | −6.54815 | 86.5 |
| No. 16 | 71–80 | M | Extremities | 54.4 | IFN-β | SD | −4.74553 | 80.8 |
| No. 17 | 61–70 | F | Trunk | 46.5 | – | PD | 17.3346 | 140.4 |
| No. 18 | 71–80 | M | Extremities | 53.7 | – | PD | −1.595225 | 93 |
| No. 19 | 51–60 | F | Head and neck | 49.2 | DTIC+IFN-β | PD | 5.457395 | 115.9 |
| No. 20 | 31–40 | M | Trunk | 78.8 | IFN-α | SD | −12.615365 | 53.7 |
| No. 21 | 61–70 | F | Trunk | 48.8 | IFN-β | PD | −1.7178157 | 96.2 |
| No. 22 | 31–40 | F | Head and neck | 52.3 | IFN-β | PD | 3.88229 | 120.1 |
| No. 23 | 71–80 | F | External genitalia | 59.1 | – | SD | −3.34502 | 92.1 |
| No. 24 | 71–80 | F | External genitalia | 53.4 | IFN-β | SD | −7.38773 | 70.5 |
| No. 25 | 61–70 | F | Extremities | 47.0 | – | PD | −4.11263 | 64 |
| No. 26 | 61–70 | M | Unknown | 53.6 | – | PD | −3.78005 | 75.6 |
| No. 27 | 61–70 | F | Extremities | 60.9 | IFN-β | PD | −0.54818 | 95.9 |
| No. 28 | 61–70 | F | Head and neck | 41.6 | IFN-α | PD | −1.456879 | 80.8 |
| No. 29 | 71–80 | M | Trunk | 56 | – | PD | −0.71335 | 77.2 |
| No. 30 | 41–50 | F | External genitalia | 69.2 | – | PD | −0.170996 | 94.4 |
| No. 31 | 71–80 | F | Extremities | 53.3 | – | PD | −0.682222 | 85.8 |
| No. 32 | 61–70 | M | Extremities | 61 | – | SD | 2.202349 | 183.2 |
| No. 33 | 71–80 | M | Unknown | 55 | – | PD | 0.328041 | 107.4 |
| No. 34 | 61–70 | F | Extremities | 68 | – | SD | 0.228017 | 106.3 |
| No. 35 | 71–80 | M | Extremities | 59.3 | IFN-β | SD | −1.7178157 | 96.2 |
| No. 36 | 61–70 | M | Unknown | 49.1 | – | PD | 0.428485 | 117.4 |
| No. 37 | 61–70 | M | Head and neck | 61 | – | SD | 0.164125 | 110.7 |
| No. 38 | 41–50 | F | External genitalia | 56 | – | SD | 1.268748 | 247.2 |
| No. 39 | 71–80 | F | Extremities | 47 | – | PD | −0.721186 | 86.1 |
| No. 40 | 41–50 | M | Head and neck | 103 | DTIC | PD | −0.111639 | 98 |
| No. 41 | 61–70 | M | Extremities | 73 | IFN-β | SD | 0.421323 | 113.8 |
| No. 42 | 31–40 | M | Extremities | 63.5 | – | PD | 0.9897167 | 102.1 |
| No. 43 | 71–80 | F | Extremities | 66.2 | – | SD | 7.3643392 | 116.5 |
| No. 44 | 71–80 | M | Extremities | 63.7 | IFN-β | PD | −7.0989841 | 91.9 |
| No. 45 | 71–80 | M | Head and neck | 57.4 | – | PD | −0.5957191 | 98.4 |
| No. 46 | 41–50 | M | Extremities | 62.7 | IFN-β | PD | 2.4247196 | 105.7 |
CBDCA, carboplatin; PTX, paclitaxel; DTIC; dacarbazine; TMZ, temozolomide; DAV, dacarbazine + nimustine hydrochloride + vincristine. Serum level changes of sCD163 from each patient (n = 59) between day 42 and day 0 were examined by ELISA. Data for each donor represent the means of duplicate assays.